O051. Chronic migraine and onabotulinumtoxinA: a prospective study on patients treated at the Headache Centre of the Padua University and analysis of possible predictors of responsivity 
Materials and methods
By compiling a headache diary, efficacy parameters (mean reduction of headache days and hours) were evaluated at 90 days after the first cycle. We analyzed also: 30% and 50% response rates and the percent of firsttime responders to II cycle; association with headache related symptoms and comorbidities (depression/anxiety disorders, hypertension, sleep disturbances, caffeine intake, BMI >30).
Results
Forty patients were evaluated (35 F, 5 M; mean age, 53±12. 
Conclusions
OnabotulinumtoxinA treatment appears useful also in a clinical setting with high presence of MOH. Responsive patients are <65 years old and have a higher frequency of severe headache and a lower share of mild headache. Depression/anxiety disorders are associated also to a lower responsiveness trend at limit of significance. Written informed consent to publication was obtained from the patient(s).
